Cd25 binding molecules
CA 2038279 C · Owner: Cammisuli, Salvatore · Inventors: Akbar, Arne N.; Amlot, Peter L.; Cammisuli, Salvatore
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or humanized forms, immunoconjugates or antibody fragments (generally described as binding molecules). The products are useful for the prophylaxis or treatment of transplant rejection paticularly in, combination with other antibodies to activated T-cells for example, CD7 antibodies.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 14, 1991 and granted March 9, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 14, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 14, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.